PMID- 37184681
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 11
DP  - 2023 Sep
TI  - The effect of concomitant proton pump inhibitor use on survival outcomes of 
      Nivolumab-treated renal cell carcinoma patients: a multicenter study.
PG  - 9183-9189
LID - 10.1007/s00432-023-04844-6 [doi]
AB  - AIM: We aimed to evaluate the effect of concomitant proton pump inhibitors (PPI) 
      use with nivolumab on survival outcomes in metastatic renal cell carcinoma (mRCC) 
      in second-line setting. METHODS: The study was designed as a multicenter and 
      retrospective involving patients with metastatic renal cell carcinoma receiving 
      second-line nivolumab therapy. One hundred and nine patients with mRCC were 
      divided into two groups based on whether they use PPI concomitantly with 
      nivolumab: concomitant PPI users and non-users. Overall survival (OS) and 
      progression-free survival (PFS) were compared between the groups with and without 
      concurrent PPIs. RESULTS: Of 109 patients in our study, 59 were not using PPI 
      concomitantly with nivolumab and 50 were using PPI concomitantly. The median PFS 
      was 6.37 (5.2-7.5) months in the concomitant PPI group and 9.7 (4.5-15) months in 
      the non-users (p = 0.03). The median OS was 14.6 (7.1-22.1) months in patients on 
      PPI concurrently with nivolumab and 29.9 (17.1-42.7) months in the non-users 
      (p = 0.01). Accordingly, PPI use for PFS (Non-use vs. Use = HR: 0.44, 95%Cl 
      0.28-0.96, p = 0.014) and PPI use for OS (Non-use vs. Use = HR: 0.68, 95%Cl 
      0.22-0.88, p = 0.01) were found to be as independent risk factors. CONCLUSIONS: 
      Concomitant use of PPIs is associated with worse survival outcomes in patients 
      with mRCC treated with nivolumab. Clinicians should carefully consider the 
      concomitant use of PPIs in such patients.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Ugrakli, Muzaffer
AU  - Ugrakli M
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey. mugrakli@gmail.com.
FAU - Kocak, Mehmet Zahid
AU  - Kocak MZ
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Dinc, Gulhan
AU  - Dinc G
AD  - Department of Medical Oncology, Okmeydani Training and Research Hospital, 
      Istanbul, Turkey.
FAU - Genc, Tugrul Burak
AU  - Genc TB
AD  - Department of Medical Oncology, Akdeniz University, Antalya, Turkey.
FAU - Caglayan, Melek
AU  - Caglayan M
AD  - Department of Medical Oncology, Selcuk University, Konya, Turkey.
FAU - Ugrakli, Selin
AU  - Ugrakli S
AD  - Department of Medical Microbiology, Necmettin Erbakan University, Konya, Turkey.
FAU - Hendem, Engin
AU  - Hendem E
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Er, Muhammed Muhiddin
AU  - Er MM
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Caglayan, Dilek
AU  - Caglayan D
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Eryilmaz, Melek Karakurt
AU  - Eryilmaz MK
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Araz, Murat
AU  - Araz M
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
FAU - Geredeli, Caglayan
AU  - Geredeli C
AD  - Department of Medical Oncology, Okmeydani Training and Research Hospital, 
      Istanbul, Turkey.
FAU - Tatli, Ali Murat
AU  - Tatli AM
AD  - Department of Medical Oncology, Akdeniz University, Antalya, Turkey.
FAU - Eren, Orhan Onder
AU  - Eren OO
AD  - Department of Medical Oncology, Selcuk University, Konya, Turkey.
FAU - Artac, Mehmet
AU  - Artac M
AD  - Meram Faculty of Medicine Department of Medical Oncology, Necmettin Erbakan 
      University, 14280, Konya, Turkey.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230515
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 31YO63LBSN (Nivolumab)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - Nivolumab
MH  - Proton Pump Inhibitors/therapeutic use
MH  - *Kidney Neoplasms/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Nivolumab
OT  - Proton pump inhibitor
OT  - Renal cell carcinoma
OT  - Survival
EDAT- 2023/05/15 13:06
MHDA- 2023/07/31 06:43
CRDT- 2023/05/15 11:14
PHST- 2023/04/07 00:00 [received]
PHST- 2023/05/07 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/05/15 13:06 [pubmed]
PHST- 2023/05/15 11:14 [entrez]
AID - 10.1007/s00432-023-04844-6 [pii]
AID - 10.1007/s00432-023-04844-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Sep;149(11):9183-9189. doi: 
      10.1007/s00432-023-04844-6. Epub 2023 May 15.